> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-11/
- Published: 2020-02-09T12:00:00.000Z
- Updated: 2026-09-14T16:02:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145935

[**2 Guides on Drug Interaction Studies**](https://www.fdaweb.com/2-guides-on-drug-interaction-studies/)  
*Federal Register* notice: FDA releases two final guidances on drug interaction studies. 02/7/2020

[**Priority Review Voucher for Vyondys 53 Approval**](https://www.fdaweb.com/priority-review-voucher-for-vyondys-53-approval/)  
*Federal Register* notice: FDA issues a priority review voucher for the approval of a rare pediatric disease product application — Sarepta Therapeutics’ Vyondys 53 (golodirsen) for treating Duchenne muscular dystrophy. 02/7/2020

[**Draft Guide for Levonorgestrel ANDAs**](https://www.fdaweb.com/draft-guide-for-levonorgestrel-andas/)  
*Federal Register* notice: FDA makes available a revised draft guidance entitled “Draft Guidance for Levonorgestrel. 02/6/2020

[**Oncologic Panel to Review 2 Product Submissions**](https://www.fdaweb.com/oncologic-panel-to-review-2-product-submissions/)  
*Federal Register* notice: FDA announces a 2/26 Oncologic Drugs Advisory Committee meeting that will discuss a Steba Biotech NDA for prostate cancer and an Eli Lilly supplemental BLA for Cyramza (ramucirumab) for use in combination with erlotinib in lung cancer patients. 02/6/2020

[**Animal User Fee Reporting Info Collection**](https://www.fdaweb.com/animal-user-fee-reporting-info-collection/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Reporting Associated With Animal Drug and Animal Generic Drug User Fees.” 02/5/2020

[**Info Collection on Electronic Product Radiation**](https://www.fdaweb.com/info-collection-on-electronic-product-radiation/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Electronic Products — 21 CFR Parts 1000 Through 1050.” 02/5/2020

[**Cardene Not Withdrawn Over Safety/Efficacy: FDA**](https://www.fdaweb.com/cardene-not-withdrawn-over-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Chiesi USA’s Cardene (nicardipine hydrochloride) injection, 25 mg/10 ml, was not withdrawn from sale for safety or effectiveness reasons. 02/4/2020